ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Interleukins"

  • Abstract Number: L19 • ACR Convergence 2021

    Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Jürgen Rech4, Leonore Unger5, Hans-Peter Tony6, Meryl Mendelson7, Christian Sieder8, Meron Maricos8 and Jens Thiel9, 1Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, 3Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 5Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, 6Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma GmbH, Nuremberg, Germany, 9Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
  • Abstract Number: 1360 • ACR Convergence 2021

    Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study

    Maria Antonietta D'Agostino1, Georg Schett2, Corine Gaillez3, Carlos Guerrero4, PETRA HANOVA5, Tomas Cazenave6, Maria S. Stoenoiu7, Marina Backhaus8, Gael Mouterde9, Maarten Boers10, Anne-Marie Duggan11, Punit Goyanka12 and Philip Conaghan13, 1Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, 2Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, 3Novartis Pharma AG, Basel, Switzerland, 4Dermatologico Country, Jalisco, Mexico, 5Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic, 6Instituto de Rehabilitación Psicofisica, Buenos Aires, Argentina, Buenos Aires, Argentina, 7Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 8Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, Berlin, Germany, 9Rheumatology department, CHU Montpellier, Montpellier, France, 10Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, 12Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, 13Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Power Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool to visualize a wide range of articular and periarticular inflammation in psoriatic arthritis (PsA).1,2…
  • Abstract Number: 1361 • ACR Convergence 2021

    Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study

    Uta Kiltz1, Petros Sfikakis2, Nicola Gullick3, Gkikas Katsifis4, Anna Kandyli5, Jan Brandt-Jrgens6, Philippe Goupille7, Nicola Maiden8, Karl Gaffney9, Maher Aassi10, Barbara Schulz10, Effie Pournara10 and Piotr Jagiello10, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 3University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, 4Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, 5Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, 6Rheumatologische Schwerpunktpraxis, Berlin, Germany, 7University hospital of Tours, Rheumatology department, Tours, France, 8Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown, Craigavon BT63 5QQ, Craigavon, United Kingdom, 9Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, 10Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab (SEC) has demonstrated long-lasting efficacy and a favorable safety profile in patients (pts) with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) across Phase…
  • Abstract Number: 1438 • ACR Convergence 2021

    Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions

    Renan Vergara1, Alex Chen1, Jerry Chen1, Marianne Riley1, Luis Blancas-Mejia1, Christie Mortales1, Tania Berrocal1, Tanu Priya1, Marsha Mason1, Kevin Yu1, Olga Sharapova1, Jorgen Nelson1, Alfredo Quijano-Rubio1, Thomas Linsky1, Ryan Swanson1 and Daniel-Adriano Silva2, 1Neoleukin Therapeutics, Inc., Seattle, WA, 2Formerly of Neoleukin Therapeutics, Inc., Seattle, WA

    Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…
  • Abstract Number: 1453 • ACR Convergence 2021

    Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease

    Rohit Gaurav1, Ted Mikuls1, Geoffrey Thiele1, Bryant England1, Madison Wolfe1, Kristina Bailey1, Amy Nelson1, Michael Duryee1, Debra Romberger1, Dana Ascherman2 and Jill Poole1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
  • Abstract Number: 1734 • ACR Convergence 2021

    Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

    Nadia Tchao1, Hamid Amouzadeh2, Nandita Sarkar1, Vincent Chow2, Xuguang Hu1, Mark Kroenke2, Hui Wang2, Rong Zhang2, Kevin Gorski1, Richard Furie3, Alan Kivitz4 and Stanley Cohen5, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Altoona Center for Clinical Research, Duncansville, PA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…
  • Abstract Number: 1827 • ACR Convergence 2021

    Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort

    Alexis Ogdie1, William Tillett2, Alun Passey3 and Patricia Gorecki4, 1University of Pennsylvania, Philadelphia, PA, 2Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Janssen Real World Evidence, HEMAR EMEA, High Wycombe, United Kingdom, 4Janssen Medical Affairs, London, United Kingdom

    Background/Purpose: Skin and joint symptoms both contribute to the burden of disease in psoriatic arthritis (PsA).1 More severe skin symptoms in patients with both skin…
  • Abstract Number: 0026 • ACR Convergence 2021

    Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)

    Nadine Honke1, Tim Appel1, Matthias Schneider2 and Georg Pongratz3, 1Department of Rheumatology, Hiller Research Center Rheumatology, University Hospital Düsseldorf, Germany (* contributed equally), Düsseldorf, Germany, 2Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, 3Polyclinic and Functional Area for Rheumatology & Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany

    Background/Purpose: The milk protein αS1-Casein (CSN1S1) was described to be overexpressed in synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Recently we…
  • Abstract Number: 0030 • ACR Convergence 2021

    Interleukin-9 Enhances the Osteoclastogenesis in Rheumatoid Arthritis

    Santanu Kar1, Dipendra Mitra2, Vijay Kumar D1 and Sushmita Chakraborty1, 1AIIMS, New Delhi, India, 2ALL INDIAN INSTITUTE OF MEDICAL SCIENCES, New Delhi, India

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation leading to bone destruction. Bone erosion in RA results from excessive resorption…
  • Abstract Number: 0032 • ACR Convergence 2021

    IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis

    Adela Navratilova1, Lucie Andrés Cerezo1, Hana Hulejová2, Viktor Bečvář2, Michal Tomcik3, Dana Tegzova2, Martina Olejárová1, David Veigl4, Karel Pavelka3, Jiri Vencovsky2 and Ladislav Senolt3, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4First Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…
  • Abstract Number: 0197 • ACR Convergence 2021

    Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series

    Hildrun Haibel1, Stefan Angermair2, Michael Schumann2, Janis Vahldiek3, Denis Poddubnyy4 and Thomas Schneider2, 1Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Charité University Medicine Berlin Campus Benjamin Franklin, Berlin, Germany, 3Charité University Medicine Berlin, Berlin, Germany, 4Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating…
  • Abstract Number: 0728 • ACR Convergence 2021

    Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study

    Philip Conaghan1, Xavier Chevalier2, Linda Mindeholm3, Ursula Schramm3, Jens Praestgaard3, Abdelkader Seroutou3, Ronenn Roubenoff3 and Matthias Schieker3, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, 3Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland

    Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
  • Abstract Number: 1131 • ACR Convergence 2021

    Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance

    Ivars Veckalns and Anna Mihailova, Riga Stradins University, Riga, Latvia

    Background/Purpose: Inflammatory arthritis (IA) treated with disease modifying antirheumatic drugs lead to secondary osteoarthritis (OA) due to inflammation, aging, and other factors. Inflammatory arthritis can…
  • Abstract Number: 1354 • ACR Convergence 2021

    Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database

    William Tillett1, Alexis Ogdie2, Patricia Gorecki3 and Alun Passey4, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Pennsylvania, Philadelphia, PA, 3Janssen Medical Affairs, London, United Kingdom, 4Janssen Real World Evidence, HEMAR EMEA, High Wycombe, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis (PsO) and multiple comorbidities.1 Approximately one-third of patients with PsO develop PsA during…
  • Abstract Number: L07 • ACR Convergence 2020

    Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial

    John Stone1, 1Massachusetts General Hospital, Boston, MA

    Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies